论文部分内容阅读
目的 :探究使用布地奈德福莫特罗治疗非急性发作期哮喘-慢性阻塞性肺疾病重叠综合症(ACOS)的疗效。方法 :针对20例ACOS患者口服班布特罗片治疗,并归为对照组,针对另外20例患者使用布地奈德福莫特罗干粉剂一次160ug/4.5ug,一日2次,吸入治疗,并归为观察组,观察两组患者肺功能情况并进行比较,两组共40例慢性阻塞性肺疾病危险程度分组B组非急性发作期ACOS患者均为我院2014年6月到2016年5月间收治。结果 :观察两组患者的肺功能情况发现,其在治疗前均未出现明显差异,经过治疗观察组患者情况明显较优,组间比较差异具有统计学意义(P<0.05)。针对两组患者的治疗有效率进行比较发现,观察组患者90.0%明显较高(对照组为70.0%),组间比较差异具有统计学意义(P<0.05)。两组不良反应发生率均为5.0%,组间比较差异不具有统计学意义(P>0.05)。结论 :使用布地奈德福莫特罗干粉剂吸入治疗哮喘-慢性阻塞性肺疾病重叠综合征较口服班布特罗片剂能够更好的改善患者临床症状,同时使得患者的肺功能得到改善,生活质量更高,且不会对患者产生严重的不良反应影响,因而用药相对安全,故值得我们在临床中借鉴。
Objective: To investigate the efficacy of budesonide formoterol in the treatment of non-acute exacerbation of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). Methods: A total of 20 patients with ACOS were treated with oral administration of bambuterol and divided into control group. Another 20 patients were treated with budesonide formoterol once daily by 160ug / 4.5ug twice a day for inhalation and Were divided into observation group and observe the lung function of two groups of patients and compared two groups of 40 patients with chronic obstructive pulmonary disease risk group B non-acute ACOS patients were hospital from June 2014 to May 2016 Between treatment. Results: The lung function of the two groups was observed. There was no significant difference between the two groups before treatment. The patients in the observation group were better than those in the control group. The difference between the two groups was statistically significant (P <0.05). According to the comparison of therapeutic efficacies between the two groups, 90.0% of patients in the observation group were significantly higher (70.0% in the control group), and the difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in both groups were 5.0%, with no significant difference between the two groups (P> 0.05). CONCLUSIONS: The use of budesonide formoterol dry powder inhalation in the treatment of asthma-COPD overlap syndrome is associated with better clinical outcomes than oral bambuterol tablets and at the same time improves patient’s lung function, life Higher quality, and will not have serious adverse reactions to patients, so the medication is relatively safe, it is worth our reference in the clinic.